Which is the right FMRP for Therapeutic Development of Fragile X Syndrome?

With a 2-year, $90,000 grant from FRAXA Research Foundation in 2016, Dr. Samie Jaffrey from Weill Medical College of Cornell University will research which FMRP is right for therapeutic development of Fragile X syndrome.

Samie Jaffrey, PhD, at Weill Medical College of Cornell University, FRAXA research grant
$90,000 Grant
Samie Jaffrey, PhD

Principal Investigator

Jiahui Wu, PhD

Postdoctoral Fellow

Wen-Biao Gan, PhD
Collaborating Investigator
Cornell University
2016 FRAXA Research Grant
$90,000 over 2 Years

A major challenge in developing therapeutics for Fragile X syndrome is the fact that normally there are many forms of the Fragile X protein (FMRP). This one protein regulates various pathways in different cell compartments of both neuronal and non-neuronal cells. It is difficult to determine which FMRP-regulated pathway needs to be corrected to improve clinical outcomes in FXS.

To definitively answer the above questions, we propose to develop a highly robust method to selectively restore protein expression in a compartment-specific and cell-specific
manner of live animals and determine if this reverses synaptic and spine defects. Our long-term goal is to indentify druggable targets for FXS therapeutic development.

Explore Current Fragile X Research

FRAXA-funded researchers around the world are leading the way towards effective treatments and ultimately a cure.